CLOs on the Move

Genzyme

www.genzyme.com

 
Genzyme Corporation is a fully owned subsidiary of Sanofi. Before its acquisition in 2011, Genzyme was an American biotechnology company based in Cambridge, Massachusetts. In 2010, Genzyme was the world`s third-largest biotechnology company, employing more than 11,000 people around the world. As a subsidiary of Sanofi, Genzyme has a presence in approximately 40 countries, including 17 manufacturing facilities and 9 genetic-testing laboratories, its products are sold in 90 countries. In 2007, Genzyme generated $3.8 billion in revenues with more than 25 products in the market. In 2006 and 2007 Genzyme was named one of Fortune Magazine`s “100 Best Companies to ...
  • Number of Employees: 50K-100K
  • Annual Revenue: > $1 Billion
  • www.genzyme.com
  • 500 Kendall Street
    Cambridge, MA USA 08807
  • Phone: 908.981.5000

Executives

Name Title Contact Details
Joann Nestor
General Counsel Profile

Similar Companies

RxAlly

RxAlly was developed to provide a new solution to the critical issues of providing additional access to care and ensuring effective health care spending at a time when prescription medicine misuse is associated with $290 billion in annual costs. The RxAlly network of pharmacies aims to improve patient health through enhanced pharmacist care that combines clinical research, evidence-based clinical services and an interoperable technology platform.

Community Memorial Hospital

The mission of Community Memorial Hospital is to improve and enhance the health and well being of individuals and our community through education, prevention, treatment and intervention.

PetDx

PetDx® – The Liquid Biopsy Company for Pets™ is a molecular diagnostics company dedicated to unleashing the power of genomics to improve pet health.

Ovid Therapeutics

Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid`s drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in adolescents with Angelman and Fragile X syndrome to identify doses suitable for younger patients.

Hanger

Built on the legacy of James Edward Hanger, the first amputee of the American Civil War, Hanger, Inc. (NYSE: HGR) delivers orthotic and prosthetic (O&P) patient care, and distributes O&P products and rehabilitative solutions to the broader market. Hanger`s Patient Care segment is the largest owner and operator of O&P patient care clinics with in excess of 730 locations nationwide. Through its Products and Services segment, Hanger distributes branded and private label O&P devices, products and components, and provides therapeutic solutions. Steeped in over 150 years of clinical excellence and innovation, Hanger`s vision is to be the partner of choice for products and services that enhance human physical capability. Hanger helps those with limb loss, paralysis, and other physical challenges become productive members of society after injury or illness. Headquartered in Austin, TX and with locations in 45 states, our employees provide personal independence, increased mobility, and restored functionality.